Carlos Ortega-Expósito, Maria Pla, Miriam Campos, Catalina Falo, Hector Perez-Montero, Juan Azcarate, Ana Benítez, Sira Salinas, Jan Bosch, Marina Aranguena-Peñacoba, Sonia Pernas, Jordi Ponce, Amparo Garcia-Tejedor
Hospital Universitario de Bellvitge, Gynecology, Hospitalet de Llobregat, Barcelona, Spain; Universitat de Barcelona, Facultat de Medicina, Departament de Ciències Clíniques, Hospitalet de Llobregat, Barcelona, Spain; IDIBELL, Instituto de Investigación biomédica de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain.
Hospital Universitario de Bellvitge, Gynecology, Hospitalet de Llobregat, Barcelona, Spain.
Clin Breast Cancer. 2025 Apr;25(3):268-276. doi: 10.1016/j.clbc.2024.12.003. Epub 2024 Dec 7.
To validate the Axillary Reverse Mapping (ARM) technique with indocyanine green (ICG), focusing on the detection rate and the procedure's feasibility. The predictive factors for metastatic involvement of ARM nodes are also analyzed to define the target population for ARM indication.
This prospective, observational, non-randomized study of patients with breast cancer included patients with an indication for axillary lymph node dissection (ALND) performed between June 2021 and June 2023. Participants were divided into two cohorts based on pattern of ICG migration: standard technique (all ARM nodes) and targeted technique (in contact with axillary vein). The feasibility of identifying and preserving ARM nodes during ALND was assessed. Multivariate logistic regression was used to analyze predictive factors (eg, tumor size, molecular surrogate subtype, multifocality, and neoadjuvant therapy) for metastatic ARM nodes.
Of the 41 patients in whom we performed the ARM technique, ARM nodes were identified and preserved after ALND in 36 patients (87.8%). Of these, 17 (89.5%) underwent the standard technique and 19 (86.4%) underwent the targeted technique. ARM metastases were identified in 12 patients: 9 (47.1%) with the standard technique and 3 (15.7%) with the targeted technique (P = .026). The ARM technique was the only risk factor for ARM involvement (odds ratio, 15.9; 95% confidence interval, 1.1-218.6).
ICG facilitates the successful completion of ARM in almost 90% of patients undergoing ALND. In addition, by selecting the ARM nodes closest to the axillary vein, the number of cross metastases can be significantly reduced.
使用吲哚菁绿(ICG)验证腋静脉逆向造影(ARM)技术,重点关注检测率和该操作的可行性。还分析了ARM淋巴结转移受累的预测因素,以确定ARM适应症的目标人群。
这项针对乳腺癌患者的前瞻性、观察性、非随机研究纳入了2021年6月至2023年6月期间有腋窝淋巴结清扫术(ALND)指征的患者。根据ICG迁移模式将参与者分为两个队列:标准技术组(所有ARM淋巴结)和靶向技术组(与腋静脉接触)。评估了在ALND期间识别和保留ARM淋巴结的可行性。采用多因素逻辑回归分析转移性ARM淋巴结的预测因素(如肿瘤大小、分子替代亚型、多灶性和新辅助治疗)。
在我们对其实施ARM技术的41例患者中,36例(87.8%)在ALND后识别并保留了ARM淋巴结。其中,17例(89.5%)采用标准技术,19例(86.4%)采用靶向技术。12例患者被发现有ARM转移:标准技术组9例(47.1%),靶向技术组3例(15.7%)(P = 0.026)。ARM技术是ARM受累的唯一危险因素(比值比,15.9;95%置信区间,1.1 - 218.6)。
ICG有助于在近90%接受ALND的患者中成功完成ARM。此外,通过选择最靠近腋静脉的ARM淋巴结,可显著减少交叉转移的数量。